SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities Registered Pursuant to Section 12(b) of the Exchange Act:
Title of Each Class
Name of each exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders
On May 13, 2021, Strongbridge Biopharma plc (the “Company”) held its Annual General Meeting of Shareholders (“AGM”). Described below are the matters voted upon at the AGM and the voting results for each matter.
Proposal No. 1 – Election of Class III Directors. Each Class III director nominee was elected to serve a three-year term until the conclusion of the Company’s 2024 annual general meeting and until such time as his successor is duly elected and qualified.
David N. Gill
Proposal No. 2 – Ratification of Selection of Auditors and Authorization to Determine the Remuneration of the Auditors – Approved. Shareholders were asked to vote to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through its Audit Committee, to determine Ernst & Young’s remuneration.
Proposal No. 3 – Approval of the Compensation Paid to Named Executive Officers – Approved. Shareholders were asked to vote to approve, on a non-binding, advisory basis, the compensation paid to our named executive officers (the “Say-on-Pay Vote”).
Proposal No. 4 – Recommendation of the Frequency of Future Say-on-Pay Votes – 1 Year Frequency Recommended. Shareholders were asked to vote to recommend, on a non-binding, advisory basis, the frequency of future Say-on-Pay votes.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STRONGBRIDGE BIOPHARMA PLC
/s/ Richard S. Kollender
Richard S. Kollender
President, Chief Financial Officer
Date: May 14, 2021